1. Combination of novel DR5 targeting agonistic scFv antibody TR2-3 with cisplatin shows enhanced synergistic antitumor activity in vitro and in vivo
   Gaoxin Lei et al, 2018, Biomedicine & Pharmacotherapy CrossRef
2. Tumoricidal activity of combining the agonistic DR5 antibody D-6 with cisplatin in C30 cisplatin-resistant ovarian cancer in vitro and in vivo
   YAN HUANG et al, 2014, Molecular Medicine Reports CrossRef
3. TRAIL mutant membrane penetrating peptide alike (TMPPA) TRAIL-Mu3 enhances the antitumor effects of TRAIL in vitro and in vivo
   Hong Zhu et al, 2017, Molecular Medicine Reports CrossRef
4. Restoring TRAIL Mediated Signaling in Ovarian Cancer Cells
   Ammad Ahmad Farooqi et al, 2014, Archivum Immunologiae et Therapiae Experimentalis CrossRef
5. The Synergistic Effects of Low Dose Fluorouracil and TRAIL on TRAIL-Resistant Human Gastric Adenocarcinoma AGS Cells
   Hong Zhu et al, 2013, BioMed Research International CrossRef
6. Zinc complex of tryptophan appended 1,4,7,10-tetraazacyclododecane as potential anticancer agent: Synthesis and evaluation
   Anupriya Adhikari et al, 2017, Bioorganic & Medicinal Chemistry CrossRef
7. DNA damage response and repair in ovarian cancer: Potential targets for therapeutic strategies
   Mohammad Mirza-Aghazadeh-Attari et al, 2019, DNA Repair CrossRef